A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH | Zendy

Sven Francque | Zendy; Pierre Bédossa | Zendy; Vlad Ratziu | Zendy; Quentin M. Anstee | Zendy; Elisabetta Bugianesi | Zendy; Arun J. Sanyal | Zendy; Rohit Loomba | Zendy; Stephen A. Harrison | Zendy; R. Balabanska | Zendy; Lyudmila Mateva | Zendy; Nicolas Lanthier | Zendy; Naim Alkhouri | Zendy; Christophe Moreno | Zendy; Jörn M. Schattenberg | Zendy; Diana Stefanova-Petrova | Zendy; Luisa Vonghia | Zendy; Roman Rouzier | Zendy; Maéva Guillaume | Zendy; Alexander Hodge | Zendy; Manuel RomeroGómez | Zendy; Philippe Huot-Marchand | Zendy; Martine Baudin | Zendy; MariePaule Richard | Zendy; JeanLouis Abitbol | Zendy; Pierre Broqua | Zendy; JeanLouis Junien | Zendy; Manal F. Abdelmalek | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH

Author(s) -

Sven Francque,

Pierre Bédossa,

Vlad Ratziu,

Quentin M. Anstee,

Elisabetta Bugianesi,

Arun J. Sanyal,

Rohit Loomba,

Stephen A. Harrison,

R. Balabanska,

Lyudmila Mateva,

Nicolas Lanthier,

Naim Alkhouri,

Christophe Moreno,

Jörn M. Schattenberg,

Diana Stefanova-Petrova,

Luisa Vonghia,

Roman Rouzier,

Maéva Guillaume,

Alexander Hodge,

Manuel RomeroGómez,

Philippe Huot-Marchand,

Martine Baudin,

MariePaule Richard,

JeanLouis Abitbol,

Pierre Broqua,

JeanLouis Junien,

Manal F. Abdelmalek

Publication year - 2021

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa2036205

Subject(s) - nonalcoholic steatohepatitis , agonist , peroxisome proliferator activated receptor , ppar agonist , peroxisome , receptor , steatohepatitis , medicine , chemistry , pharmacology , endocrinology , nonalcoholic fatty liver disease , fatty liver , disease

Management of nonalcoholic steatohepatitis (NASH) is an unmet clinical need. Lanifibranor is a pan-PPAR (peroxisome proliferator-activated receptor) agonist that modulates key metabolic, inflammatory, and fibrogenic pathways in the pathogenesis of NASH.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research